{"id":"39cfcdbb-90dc-4ee5-91e8-551c4850c240","url":"content/39cfcdbb-90dc-4ee5-91e8-551c4850c240","title":"Overall survival at 1 - year follow up","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic evidence commentable-section\" data-annot-id=\"topic.dita_f95adae5-7a8d-4cd9-985c-9189421864b9\" id=\"topic.dita_f95adae5-7a8d-4cd9-985c-9189421864b9\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  <div class=\"body evidence-text\">\n    <p class=\"p\">Overall survival at 1-year follow up was 98.2% for people who had trastuzumab compared with 97.6% for people who had observation only. This is a 24% relative reduction in mortality. </p>\n    <p class=\"p\">At 2-year follow up, 3.5% of people died in the trastuzumab group, compared with 5% in the observation group. This gives an unadjusted hazard ratio (HR) of 0.66 (0.45 to 0.87), p=0.0115. Distant metastases were 9% in the trastuzumab group and 14% in the observation group. This gives an absolute time to distant recurrence event-free survival benefit of 6.3% at 3 years (85.7% versus 79.4%),79.4%), p&lt;0.0001.</p>\n  </div>\n<nav class=\"related-links\" role=\"navigation\"><div class=\"familylinks\"><div class=\"parentlink\"><strong>Parent topic:</strong> <a class=\"link\" href=\"content/b14ded4e-69fe-466d-b552-85189aa14568\" href_s=\"SD00835148\">Clinical evidence</a></div></div></nav></article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835122","url_s":"content/39cfcdbb-90dc-4ee5-91e8-551c4850c240","title_s":"Overall survival at 1 - year follow up","nextTopic_s":"acf79553-cd6f-4898-86c1-053288e6eb2a","prevTopic_s":"9f3cdfe3-40cc-466f-9a2d-9668cf1343d2"},"nice":{"nice_infotype_s":"evidence","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":"","nice_condition-disease_s":"BreastCancer"}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"39cfcdbb-90dc-4ee5-91e8-551c4850c240","contentjoinuuid":"c986b0d8-cde7-403e-8864-3b24ee8a3d85","contentjoinuuids":["c986b0d8-cde7-403e-8864-3b24ee8a3d85","b6411394-b182-48a0-932b-feab3de553ac","3bf546c1-e94d-4f23-82d4-d18f30a58030","fa65bb0c-da11-4d20-af93-88079f697ada","5d4c452b-83f9-4d93-a3fb-6f79c3e48727"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}